In the final part of his conversation with Pharmaceutical Executive, Ken Keller discusses what his expectations are following the healthcare conference.
Ken Keller
Advertisement
Articles by Ken Keller
Why Was There Such an Emphasis on Data Collection at this Year's Conference?
Published: | Updated:
Ken Keller, Daiichi Sankyo’s head of global oncology and CEO of US operations, discusses the importance of bringing quality data to the JP Morgan Healthcare Conference.
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference?
Published: | Updated:
Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.
Advertisement
Latest Updated Articles
Why Was There Such an Emphasis on Data Collection at this Year's Conference?Published: January 19th 2026 | Updated: January 22nd 2026
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference?Published: January 16th 2026 | Updated: January 22nd 2026
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program
5